Portola Pharmaceuticals Raises $89M
South San Francisco-based Portola Pharmaceuticals announced Monday that it has raised $89M in a preferred stock financing round. The firm, which is developing therapeutics aimed at cardiovascular and autoimmune/inflammatory disease, said the funding came from Temasek, Eastern Capital Limited, and existing investors. Portola said the funds wlil go towards betrixaban, which is in Phase 3 clinical development for inhibiting the activity of Factor Xa, which is involved in controlling coagulation of blood.
posted on Monday, November 21, 2011 (Link to more information)
Related companies:
Portola Pharmaceuticals
Related stories:
> Portola Pharmaceuticals Lands $60M
> Portola Pharmaceuticals Gets $70M In Series C
> Third Rock Ventures Raises $426M Fund, Sets Up Shop In San Francisco
> Gene Security Network Raises $4M
> Bridge Pharmaceuticals Raises $35M
silicontap.com Home